New study tracks antibody drugs for rare nerve disease in 200 patients
NCT ID NCT06885957
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study is tracking how well different monoclonal antibody treatments work for people with a rare autoimmune disease called neuromyelitis optica spectrum disorder (NMOSD). The disease causes the immune system to attack the nerves in the eyes and spine. The study will follow 200 adults in China who have a specific antibody (AQP4-IgG) and are receiving these treatments in real-world clinics. Researchers will measure how often relapses happen, changes in disability, and any side effects over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMO SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.